NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $104.66 +2.71 (+2.66%) (As of 12:21 PM ET) Add Compare Share Share Today's Range$101.60▼$104.8050-Day Range$77.70▼$123.6252-Week Range$50.20▼$126.89Volume297,839 shsAverage Volume1.02 million shsMarket Capitalization$7.25 billionP/E Ratio15.98Dividend YieldN/APrice Target$126.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Lantheus alerts: Email Address Lantheus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside23.1% Upside$126.00 Price TargetShort InterestBearish5.40% of Shares Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment1.16Based on 11 Articles This WeekInsider TradingSelling Shares$3.95 M Sold Last QuarterProj. Earnings Growth11.35%From $5.99 to $6.67 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.70 out of 5 starsMedical Sector16th out of 911 stocksDiagnostic Substances Industry1st out of 13 stocks 3.4 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lantheus' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.40% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 3.4 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Lantheus this week, compared to 6 articles on an average week.Search InterestOnly 20 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat Follows8 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,949,202.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 11.35% in the coming year, from $5.99 to $6.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 15.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 15.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 148.38.Price to Book Value per Share RatioLantheus has a P/B Ratio of 8.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market JARYour Ticket to the Future $75B Air Mobility Market Boom?Looking for the next big investment opportunity? This company could be your chance to catch the electric aviation wave.Explore their Financial Opportunity Today About Lantheus Stock (NASDAQ:LNTH)Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesAugust 15, 2024 | insidertrades.comLantheus Holdings, Inc. (NASDAQ:LNTH) Director Gerard Ber Sells 15,500 SharesAugust 13, 2024 | insidertrades.comLantheus Holdings, Inc. (NASDAQ:LNTH) President Paul Blanchfield Sells 2,000 SharesSeptember 12, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 11 at 4:13 AM | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 5, 2024 | msn.comRedburn Atlantic Initiates Coverage of Lantheus Holdings (LNTH) with Buy RecommendationSeptember 5, 2024 | globenewswire.comLantheus Appoints Julie Eastland as New Board MemberSeptember 5, 2024 | americanbankingnews.comLantheus (NASDAQ:LNTH) Now Covered by Redburn AtlanticAugust 31, 2024 | msn.comBargain Hunting for Stocks: 2 Stocks to Buy in SeptemberSeptember 12, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 28, 2024 | finance.yahoo.comWe Ran A Stock Scan For Earnings Growth And Lantheus Holdings (NASDAQ:LNTH) Passed With EaseAugust 28, 2024 | globenewswire.comLantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 16, 2024 | investing.comLantheus Holdings director sells over $1.49 million in company stockAugust 15, 2024 | finance.yahoo.comInsider Sale: Director Gerard Ber Sells 15,500 Shares of Lantheus Holdings Inc (LNTH)August 14, 2024 | finance.yahoo.comLNTH Sep 2024 80.000 call (LNTH240920C00080000)August 8, 2024 | finance.yahoo.comLantheus Holdings' (NASDAQ:LNTH) Earnings Are Weaker Than They SeemAugust 5, 2024 | markets.businessinsider.comLantheus: Strong Buy Rating on Robust Financials and Strategic Growth ProspectsAugust 3, 2024 | finance.yahoo.comLantheus- Scanning for Profits in DiagnosticsAugust 1, 2024 | seekingalpha.comLantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call TranscriptSee More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/12/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees700Year FoundedN/APrice Target and Rating Average Stock Price Target$126.00 High Stock Price Target$175.00 Low Stock Price Target$100.00 Potential Upside/Downside+23.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$6.55 Trailing P/E Ratio15.57 Forward P/E Ratio17.03 P/E GrowthN/ANet Income$326.66 million Net Margins29.80% Pretax Margin38.53% Return on Equity48.36% Return on Assets24.28% Debt Debt-to-Equity Ratio0.55 Current Ratio4.68 Quick Ratio4.41 Sales & Book Value Annual Sales$1.44 billion Price / Sales4.92 Cash Flow$6.75 per share Price / Cash Flow15.12 Book Value$11.91 per share Price / Book8.56Miscellaneous Outstanding Shares69,313,000Free Float68,273,000Market Cap$7.07 billion OptionableOptionable Beta0.50 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 65)CEO & Director Comp: $139.19kMr. Paul M. Blanchfield (Age 42)President Comp: $1.18MMr. Robert J. Marshall Jr. (Age 57)CFA, CFO & Treasurer Comp: $1.3MMr. Daniel M. Niedzwiecki (Age 46)Chief Administrative Officer, General Counsel & Corporate Secretary Comp: $920.09kDr. Jean-Claude Provost M.D.Chief Medical OfficerMs. Andrea Sabens (Age 45)Chief Accounting Officer Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMr. Mark Richard KinarneySenior Director of Investor RelationsMs. Linda S. Lennox (Age 58)VP of Corporate Communications & Chief of Staff Ms. Carol Walker (Age 61)Senior Vice President of Quality More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELCelldex TherapeuticsNASDAQ:CLDXMyriad GeneticsNASDAQ:MYGNRiot PlatformsNASDAQ:RIOTView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 13,711 shares on 9/5/2024Ownership: 0.020%Clearbridge Investments LLCBought 39,369 shares on 8/27/2024Ownership: 0.809%Dana Investment Advisors Inc.Sold 3,996 shares on 8/27/2024Ownership: 0.034%Aurora Investment CounselSold 2,145 shares on 8/22/2024Ownership: 0.044%Cetera Investment AdvisersBought 7,640 shares on 8/22/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $62.00 at the start of the year. Since then, LNTH stock has increased by 65.1% and is now trading at $102.39. View the best growth stocks for 2024 here. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings results on Wednesday, July, 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by $0.07. The business's revenue was up 22.5% compared to the same quarter last year. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Top institutional investors of Lantheus include Farallon Capital Management LLC (3.29%), Reinhart Partners LLC. (2.12%), Dimensional Fund Advisors LP (1.79%) and Hood River Capital Management LLC (1.55%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL) and Exelixis (EXEL). This page (NASDAQ:LNTH) was last updated on 9/12/2024 by MarketBeat.com Staff From Our Partners⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredRecently listed NASDAQ firm is well positioned for growth with game-changing AI platform for e-commerce.With an innovative AI platform, one tiny but growing NASDAQ firm is ushering in a new e-commerce era and is tr...Smallcaps Daily | SponsoredYour Ticket to the Future $75B Air Mobility Market Boom?Looking for the next big investment opportunity? This company could be your chance to catch the electric aviat...Market JAR | Sponsored“Why I don’t care if the Fed cuts rates” - SYKES In on Friday out by Monday Over the past decade I’ve made millions of dollars with a strategy I call Weeken...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
